Is IMMUTEP Ltd (IMMP) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 44.8% / 30% | 1.9% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 44.8% / 33% | 1.9% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.8% / 33% | 90.2% / 33% | 3.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 44.8% / 33% | 1.9% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.8% / 33% | 90.2% / 33% | 3.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -763.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -61.8% | |
| Return on Assets (ROA) | -32.1% |
Cash Flow & Balance Sheet
| Free Cash Flow | -$36M |
| Total Debt | $2M |
| Debt-to-Equity | 1.2 |
| Current Ratio | 3.0 |
| Total Assets | $202M |
Price & Trading
| Last Close | $0.36 |
| 50-Day MA | $2.29 |
| 200-Day MA | $2.03 |
| Avg Volume | 1.2M |
| Beta | 1.6 |
|
52-Week Range
$0.35
| |
About IMMUTEP Ltd (IMMP)
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IMMUTEP Ltd (IMMP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IMMUTEP Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IMMUTEP Ltd's debt ratio?
IMMUTEP Ltd's debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
What are IMMUTEP Ltd's key financial metrics?
IMMUTEP Ltd has a market capitalization of $52M. Return on equity stands at -61.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.